Baseline patient characteristics
| . | ||
|---|---|---|
| N . | % . | |
| Total | 25 | 100 |
| Age, median (range), y | 62 (34, 76) | |
| Patient sex | ||
| Male | 12 | 48 |
| Female | 13 | 52 |
| Donor sex | ||
| Male | 14 | 56 |
| Female | 11 | 44 |
| Primary disease | ||
| AML | 5 | 20 |
| CLL/SLL/PLL | 3 | 12 |
| CML | 1 | 4 |
| ALL | 3 | 12 |
| MDS | 9 | 36 |
| MPD | 2 | 8 |
| MM | 1 | 4 |
| NHL | 1 | 4 |
| ECOG performance status | ||
| 0 | 2 | 8 |
| 1 | 17 | 68 |
| 2 | 5 | 20 |
| Unknown | 1 | 4 |
| Patient CMV serological status | ||
| Negative | 24 | 96 |
| Unknown | 1 | 4 |
| Donor CMV serological status | ||
| Positive | 8 | 32 |
| Conditioning regimen intensity | ||
| Myeloablative | 14 | 56 |
| Nonmyeloablative | 11 | 44 |
| HLA molecular typing (A, B, C, DRB1) | ||
| Matched unrelated | 14 | 56 |
| Matched related | 8 | 32 |
| Mismatch unrelated | 3 | 12 |
| Graft source | ||
| Peripheral blood | 25 | 100 |
| Days from HSCT to study enrollment, median (range) | 919 (177, 2842) | |
| Days from cGVHD onset to study enrollment, median (range) | 524 (58, 2697) | |
| Prior grade I-IV acute GVHD | 10 | 40 |
| No. of cGVHD sites involvement, median (range) | 3 (2, 5) | |
| NIH consensus global cGVHD severity | ||
| Mild | 1 | 4 |
| Moderate | 18 | 72 |
| Severe | 6 | 24 |
| Daily prednisone dose, median (range), mg/kg | 0.26 (0, 0.86)* | |
| No. of prior systemic cGVHD therapies, median (range) | 2 (1, 4) | |
| No. of concurrent systemic cGVHD therapies, median (range) | 2 (0, 3)* | |
| . | ||
|---|---|---|
| N . | % . | |
| Total | 25 | 100 |
| Age, median (range), y | 62 (34, 76) | |
| Patient sex | ||
| Male | 12 | 48 |
| Female | 13 | 52 |
| Donor sex | ||
| Male | 14 | 56 |
| Female | 11 | 44 |
| Primary disease | ||
| AML | 5 | 20 |
| CLL/SLL/PLL | 3 | 12 |
| CML | 1 | 4 |
| ALL | 3 | 12 |
| MDS | 9 | 36 |
| MPD | 2 | 8 |
| MM | 1 | 4 |
| NHL | 1 | 4 |
| ECOG performance status | ||
| 0 | 2 | 8 |
| 1 | 17 | 68 |
| 2 | 5 | 20 |
| Unknown | 1 | 4 |
| Patient CMV serological status | ||
| Negative | 24 | 96 |
| Unknown | 1 | 4 |
| Donor CMV serological status | ||
| Positive | 8 | 32 |
| Conditioning regimen intensity | ||
| Myeloablative | 14 | 56 |
| Nonmyeloablative | 11 | 44 |
| HLA molecular typing (A, B, C, DRB1) | ||
| Matched unrelated | 14 | 56 |
| Matched related | 8 | 32 |
| Mismatch unrelated | 3 | 12 |
| Graft source | ||
| Peripheral blood | 25 | 100 |
| Days from HSCT to study enrollment, median (range) | 919 (177, 2842) | |
| Days from cGVHD onset to study enrollment, median (range) | 524 (58, 2697) | |
| Prior grade I-IV acute GVHD | 10 | 40 |
| No. of cGVHD sites involvement, median (range) | 3 (2, 5) | |
| NIH consensus global cGVHD severity | ||
| Mild | 1 | 4 |
| Moderate | 18 | 72 |
| Severe | 6 | 24 |
| Daily prednisone dose, median (range), mg/kg | 0.26 (0, 0.86)* | |
| No. of prior systemic cGVHD therapies, median (range) | 2 (1, 4) | |
| No. of concurrent systemic cGVHD therapies, median (range) | 2 (0, 3)* | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; ECOG, Eastern Cooperative Oncology Group; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma; PLL, prolymphocytic leukemia; SLL, small lymphocytic lymphoma.
A single patient with history of prednisone-associated psychosis was not on prednisone or other systemic therapies at the time of study entry.